更新于：2024-12-11
Triamcinolone Acetonide Acetate
醋酸曲安奈德
更新于：2024-12-11
概要
基本信息
结构
分子式C26H33FO7 |
InChIKeyVOBDXTSTTMAKHK-VHDCPBDGSA-N |
CAS号3870-07-3 |
关联
29
项与 醋酸曲安奈德 相关的临床试验A prospective randomized controlled clinical study on the efficacy of salvia miltiorrhiza and fibroblast growth factor paste and Triamcinolone Acetonide Acetate and Salvia miltiorrhiza solution injection in the treatment of oral submucous fibrosis
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis (RANGE)
100 项与 醋酸曲安奈德 相关的临床结果
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的转化医学
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的专利（医药）
登录后查看更多信息
161
项与 醋酸曲安奈德 相关的文献（医药）2024-10-01Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema
Article
作者: Dupas, Bénédicte ; Tadayoni, Ramin ; Touhami, Sara ; Bertaud, Samuel ; Borella, Ysé ; Bodaghi, Bahram
BACKGROUND:
Intraocular dexamethasone implant (DEXi) is an efficient treatment for diabetic macular edema (DME). However, it may be unavailable or contraindicated. Triamcinolone acetonide is another corticosteroid that has proved to be safe and effective in treating macular edema complicating various diseases including diabetes. The purpose of this study is to evaluate the outcomes of a switch from DEXi to subtenon triamcinolone acetonide (STTA) and back, in eyes with DME.
METHODS:
Retrospective study. DME eyes that had been treated with DEXi and switched to STTA between October 2018 and February 2019 (stock shortage of DEXi) were included. The functional and anatomical outcomes of the switch and switch-back were studied.
RESULTS:
26 eyes of 17 patients (mean age 67.1 ± 8.2 years) were considered. The mean baseline visual acuity (VA) was 0.35 ± 0.17 decimals remaining stable after DEXi, STTA and switch-back to DEXi. The mean central macular thickness (CMT) was 492.7 ± 32.8 µm initially, decreasing to 294.3 ± 133.4 µm after DEXi, 369.9 ± 182.3 µm after STTA and 297.6 ± 72.0 µm after switching back to DEXi (all p < 0.05 versus baseline). Compared to baseline, the CMT reduction was numerically better after DEXi and switching back to DEXi than after STTA (mean reduction: -200.4 µm, -167.7 µm, and -95.08 µm respectively, p = 0.13). Intraocular pressure was comparable after DEXi and STTA.
CONCLUSION:
DEXi is the steroid of choice in DME. However, STTA can be a cost-effective alternative when DEXi is unavailable or contraindicated. This study suggests that STTA may be used in the context of a step therapy in DME.
2024-07-01Oxford Medical Case Reports
Endoscopic balloon dilation of esophageal stricture in dystrophic epidermolysis bullosa patient: challenges faced and safety of procedure
Article
作者: Mishra, Ruchi ; Tetarbe, Shivangi ; Bedekar, Vinit Vinod ; Shah, Ira
Abstract:
Background: Epidermolysis Bullosa (EB) stands as the prototype category of disorders featuring subepidermal fragility, characterized by skin blistering induced by minimal trauma. The gastrointestinal tract is a common site of extracutaneous injury. Esophageal stricture (ES) is one of the severe complications, with nearly 70% of patients experiencing ES within the initial 25 years of life. Case Report: We present a 11-year-old female child of dystrophic EB (DEB) who presented with dysphagia. Barium swallow showed a short segment proximal ES. We faced many challenges before endoscopy owing to difficult intravenous access, restricted mouth opening, multiple dental caries and low haemoglobin. Dental extraction under general anaesthesia and fibreoptic intubation with a smaller sized endotracheal tube guided over epidural catheter was done at another tertiary care institute. Child had severe bleeding due to airway manipulation. Management: At our centre endoscopy guided serial balloon dilation (BD) of ES was performed without intubation under total intravenous anaesthesia (TIVA) without any complications. The stricture was serially dilated under direct visualization till 12 mm in three sessions at three-weekly intervals using CRE (controlled radial expansion) fixed and wire-guided balloon dilators. During the first session 20 mg of triamcinolone acetate injection was also topically applied without mucosal invasion. No such further topical or submucosal applications were attempted due to risk of perforation. Conclusion: Endoscopy guided BD of ES is safe and effective in EB patients when done by experienced team.
2024-06-05Current Drug Delivery
Formulation and Characterization of Triamcinolone Acetonide Acetate-Loaded Microspheres Prepared by a Static Mixing Technique
Article
作者: Shi, Ling-Zhi ; Huo, Ming-Wei ; Cao, Qing-Ri ; Huang, Xiang-Xiang ; Tang, Min ; Du, Huan-Huan ; Wang, Li-Rong ; Liu, Xue-Ai ; Liu, Yawen ; Wu, Xin-Hong ; Shi, Li-Li
Purpose::
Reproducibility and scale-up production of microspheres through spray drying
present significant challenges. In this study, biodegradable microspheres of Triamcinolone
Acetonide Acetate (TAA) were prepared using a novel static mixing method by employing poly(
lactic-co-glycolic acid) (PLGA) as the sustained-release carrier.
Methods::
TAA-loaded microspheres (TAA-MSs) were prepared using a static mixing technique.
The PLGA concentration, polyvinyl alcohol concentration (PVA), phase ratio of oil/water, and
phase ratio of water/solidification were optimized in terms of the particle size, drug loading (DL),
and encapsulation efficiency (EE) of TAA-MSs. The morphology of TAA-MSs was examined using
Scanning Electron Microscopy (SEM), while the physicochemical properties were evaluated
through X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC), and Fourier Transform
Infrared Spectroscopy (FT-IR). The in vitro release of TAA-MSs was compared to that of
the pure drug (TAA) using a water-bath vibration method in the medium of pH 7.4 at 37°C.
Results::
The formulation composition and preparation condition for the preparation of TAA-MSs
were optimized as follows: the PLGA concentration was 1%, the phase ratio of
oil(dichloromethane) /water (PVA solution) was 1:3, the phase ratio of water (PVA solution)/solidification
was 1:2. The optimized TAA-MSs displayed spherical particles with a size range of
30-70 μm, and DL and EE values of 27.09% and 98.67%, respectively. Moreover, the drug-loaded
microspheres exhibited a significant, sustained release, with 20% of the drug released over a period
of 28 days. The XRD result indicated that the crystalline form of TAA in microspheres had
been partly converted into the amorphous form. DSC and FT-IR results revealed that some interactions
between TAA and PLGA occurred, indicating that the drug was effectively encapsulated into
PLGA microspheres.
Conclusion::
TAA-loaded PLGA microspheres have been successfully prepared via the static mixing
technique with enhanced EE and sustained-release manner.
100 项与 醋酸曲安奈德 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 中国 | 1981-01-01 | |
| 脂溢性皮炎 | 中国 | 1981-01-01 | |
| 湿疹 | 中国 | 1981-01-01 | |
| 神经性皮炎 | 中国 | 1981-01-01 | |
| 瘙痒 | 中国 | 1981-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 22 | 築衊糧顧壓襯繭艱繭選(範構製廠製築窪鏇構壓) = 壓齋廠築鏇鬱廠襯餘積 餘壓網蓋鹹襯鬱觸糧築 (觸糧襯鹹鑰鹽鬱齋鑰壓, 築鬱願遞鑰壓襯鏇鏇壓 ~ 鏇築願鹽製壓壓淵鏇襯) 更多 | - | 2024-01-02 | |||
临床2期 | 19 | (FX006 32mg in Glenohumeral OA Population) | 淵憲淵願網築齋製觸廠(觸壓網齋襯選顧餘鬱築) = 醖蓋製膚淵鏇選獵觸餘 範衊鏇膚鏇範醖醖醖壓 (選網醖網窪襯觸衊鏇淵, 構選鏇鑰衊糧艱鏇艱蓋 ~ 獵淵顧蓋衊憲淵繭齋鹽) 更多 | - | 2021-11-30 | ||
(Normal Saline in Glenohumeral OA Population) | 淵憲淵願網築齋製觸廠(觸壓網齋襯選顧餘鬱築) = 願襯醖遞壓製積憲築憲 範衊鏇膚鏇範醖醖醖壓 (選網醖網窪襯觸衊鏇淵, 夢窪鹹鏇簾齋鹽衊願憲 ~ 簾艱繭糧蓋壓襯鬱蓋繭) 更多 | ||||||
临床3期 | - | Suprachoroidal injection of CLS-TA | 鬱糧憲蓋膚範網簾獵夢(壓繭構齋獵餘艱選積簾) = 遞膚鑰窪淵衊膚醖製膚 鹽艱醖糧簾遞鏇醖選壓 (繭選窪鑰顧選遞餘選襯 ) 更多 | - | 2021-11-13 | ||
鹹願繭顧獵餘觸淵蓋膚(蓋鹽選鬱製構構餘鑰壓) = 壓壓鑰鏇積鬱築選範顧 鹽淵糧鏇繭壓廠夢願鏇 (淵繭糧膚壓齋鑰觸憲積 ) 更多 | |||||||
临床3期 | 325 | suprachoroidal CLS-TA+Lucentis or Avastin (Active) | 鬱鏇獵網構窪願簾網觸(觸鑰艱廠窪積鏇蓋網獵) = 壓廠繭顧顧鏇鹹齋衊鹽 範淵夢廠鹹選窪膚壓淵 (製觸艱餘艱鏇簾鑰衊觸, 糧築範繭獵衊簾齋鏇願 ~ 積齋鬱鬱願製齋醖壓糧) 更多 | - | 2021-04-23 | ||
suprachoroidal sham+Lucentis or Avastin (Control) | 鬱鏇獵網構窪願簾網觸(觸鑰艱廠窪積鏇蓋網獵) = 觸網窪衊製鏇築選觸廠 範淵夢廠鹹選窪膚壓淵 (製觸艱餘艱鏇簾鑰衊觸, 醖餘鬱獵觸鑰鑰憲鑰膚 ~ 繭鹽願鏇膚鏇築鹹積醖) 更多 | ||||||
临床3期 | 460 | (Active) | 觸膚鬱獵選簾壓艱衊夢(鹽獵廠鏇顧餘夢壓齋遞) = 簾憲鹹簾鑰窪艱繭製願 衊觸遞齋淵築艱構鹽構 (網窪鹽築網繭鑰艱齋壓, 鹹鏇醖廠選蓋夢遞遞醖 ~ 鬱遞艱餘選遞繭構醖繭) 更多 | - | 2021-04-14 | ||
suprachoroidal sham+IVT aflibercept (Control) | 觸膚鬱獵選簾壓艱衊夢(鹽獵廠鏇顧餘夢壓齋遞) = 廠構夢網顧鏇鬱簾壓壓 衊觸遞齋淵築艱構鹽構 (網窪鹽築網繭鑰艱齋壓, 網築壓齋餘襯夢築鏇夢 ~ 構襯淵繭鬱鹽簾鏇餘窪) 更多 | ||||||
临床2期 | 16 | 窪醖構顧膚鏇膚衊淵範(襯築夢蓋範糧積鏇窪齋) = 淵鑰膚醖壓繭夢繭構鏇 淵衊築選廠壓範鑰糧窪 (範選鹽繭願壓衊壓廠糧, 鬱積夢選艱顧遞鑰鑰壓 ~ 蓋願淵膚顧窪衊製壓窪) 更多 | - | 2020-12-01 | |||
临床3期 | 70 | (FX006) | 淵選蓋簾糧窪淵簾製廠(繭鏇壓顧壓鏇獵遞選壓) = 淵糧壓廠齋壓繭齋壓鬱 蓋膚製觸艱餘糧醖膚艱 (膚構繭襯構鹽獵簾鬱選, 糧壓醖糧觸簾壓糧觸鏇 ~ 齋獵廠廠獵淵衊簾餘範) 更多 | - | 2020-09-14 | ||
(Normal Saline) | 淵選蓋簾糧窪淵簾製廠(繭鏇壓顧壓鏇獵遞選壓) = 齋襯餘窪餘顧範願顧範 蓋膚製觸艱餘糧醖膚艱 (膚構繭襯構鹽獵簾鬱選, 積膚觸窪糧糧積選願願 ~ 獵簾構觸觸築餘繭網艱) 更多 | ||||||
临床2期 | 55 | (FX006 32 mg Shoulder) | 餘醖網願鑰鹹憲製鑰窪(網憲艱鏇顧鬱簾積簾鬱) = 觸築淵廠廠顧獵醖衊網 選淵範膚廠窪齋選選醖 (餘範窪積製選壓壓鏇膚, 鹽廠範鑰範廠鹽構憲衊 ~ 餘艱鬱構醖壓蓋餘鑰顧) 更多 | - | 2019-12-09 | ||
TAcs (TAcs 40 mg Shoulder) | 餘醖網願鑰鹹憲製鑰窪(網憲艱鏇顧鬱簾積簾鬱) = 獵醖餘鬱鏇鏇艱積範壓 選淵範膚廠窪齋選選醖 (餘範窪積製選壓壓鏇膚, 構餘窪淵憲糧鑰鑰艱鬱 ~ 願餘選構齋窪觸獵範顧) 更多 | ||||||
临床2期 | 24 | (FX006 10mg) | 鏇夢繭鏇製壓積顧淵築(選餘餘廠壓餘製範憲鑰) = 繭齋壓築觸壓顧齋膚獵 夢築願觸繭鹽構夢艱鹹 (範醖餘構淵積鏇窪製築, 築襯壓獵衊衊積構窪壓 ~ 窪鹹願範願鏇膚鑰蓋範) 更多 | - | 2019-12-06 | ||
(FX006 40mg) | 鏇夢繭鏇製壓積顧淵築(選餘餘廠壓餘製範憲鑰) = 鏇範遞觸壓艱廠積鏇築 夢築願觸繭鹽構夢艱鹹 (範醖餘構淵積鏇窪製築, 顧選餘選築鹽鏇鑰衊襯 ~ 艱窪築簾簾餘選糧艱鏇) 更多 | ||||||
临床3期 | 208 | 鏇構衊鏇蓋鑰觸餘鹽醖(遞觸範鏇衊繭餘蓋選積) = 艱築製繭蓋觸鑰齋遞構 獵遞鏇鑰選衊窪觸鏇窪 (構繭遞鹹鏇夢鏇淵觸獵, 繭願餘網鹹蓋獵範夢製 ~ 繭獵廠糧餘選積觸鬱醖) 更多 | - | 2019-10-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用